Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. The company is headquartered in Zhongshan, Guangdong and currently employs 3,529 full-time employees. The company went IPO on 2020-04-24. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The firm's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.
09926.HK stock price ended at $115.1 on 水曜日, after dropping 2.13%
On the latest trading day Jan 21, 2026, the stock price of 09926.HK fell by 2.13%, dropping from $116.00 to $115.10. During the session, the stock saw a volatility of 1.31%, with prices oscillating between a daily low of $114.60 and a high of $116.10. On the latest trading day, the trading volume for 09926.HK decreased by 2.4M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.6M shares were traded, with a market value of approximately $106.0B.